Table 5 Immunological monitoring in high-grade glioma patients
Patient no. | DC injection (times) | Side effect | ELISPOT | DTH | Th1/Th2 balancea | Response | ||
|---|---|---|---|---|---|---|---|---|
Peptide | DC | KLH | ||||||
1 | 1×10 7 (12) | 1/5 (MAGE-1) | + | + | 9.38 | PD | ||
2 | 1×10 7 (24) | 4/5 (WT1-1, 1–2, MAGE-1, 3) | ++ | ++ | +++ | 0.3 | SD | |
3 | 1×10 7 (4) | N. D. b | 9.67 | PD | ||||
4 | 2×10 7 (5) | Hepatic (II) | 3/5 (WT1-1, 1–2, MAGE-3) | 4.09 | PD | |||
5 | 2×10 7 (6) | 0 | + | 6.07 | PD | |||
6 | 2×10 7 (4) | 0 | 2.77 | PD | ||||
7 | 5×10 7 (7) | 1/5 (gp100) | + | 7.08 | PD | |||
8 | 5×10 7 (6) | 3/5 (WT1-2, HER2, MAGE-3) | 71.4 | PD | ||||
9 | 5×10 7 (6) | 2/5 (MAGE-1, 3) | ++ | + | + | 7.55 | PD | |